Trilogy Capital’s West Pharmaceutical WST Stock Holding History

Trilogy Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7	Closed	-$1K	–	577
2018 Q3	$1K	Hold	7	–	–	﹤0.01%	598
2018 Q2	$1K	Buy	+7	New	+$644	﹤0.01%	556

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Trilogy Capital's WST Position: Q4 2018 in Review

Trilogy Capital sold out of West Pharmaceutical (WST) in Q4 2018, closing a stake of 7 shares — an estimated $1K sold.

Trilogy Capital first reported a position in WST in Q2 2018 and held it in 2 quarters. The position peaked at $1K in Q3 2018. 355 funds tracked by Wall St. Rank hold WST as of Q4 2018.

Trilogy Capital reported no remaining West Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 7 West Pharmaceutical shares in Q4 2018, an estimated $1K.
Trilogy Capital first reported a position in West Pharmaceutical in Q2 2018 and held it in 2 quarters.
Trilogy Capital's West Pharmaceutical position peaked at $1K in Q3 2018.
355 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.